Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?Zacks Investment Research • 08/09/24
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 08/09/24
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/07/24
Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024GlobeNewsWire • 07/31/24
Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD StudyGlobeNewsWire • 07/30/24
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/18/24
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific MeetingGlobeNewsWire • 07/10/24
This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For ThursdayBenzinga • 06/20/24
Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR StudyGlobeNewsWire • 06/13/24
Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 06/04/24
Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 ResultsSeeking Alpha • 06/01/24
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/07/24
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024GlobeNewsWire • 05/01/24
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic RetinopathyGlobeNewsWire • 04/18/24